Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (121-130 of 237) with videos related to

Pageof 24
Sort By:
Anti-Cancer Drugs|June 19, 2004
The clinical development of new mitotic inhibitors that stabilize the microtubuleSridhar Mani, Manuel Macapinlac, Sanjay Goel, et al.
Cell Cycle (Georgetown, Tex.)|April 17, 2008
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibitionMarianne S Poruchynsky, Dan L Sackett, Robert W Robey, et al.
Cancer Research|September 4, 2014
Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancersKrastan B Blagoev, Julia Wilkerson, Wilfred D Stein, et al.
The Journal of Clinical Endocrinology and Metabolism|November 21, 2014
Brain metastasis in patients with adrenocortical carcinoma: a clinical seriesMauricio Burotto, Nishant Tageja, Avi Rosenberg, et al.
Blood|March 6, 2002
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cellsMasaki Kitazono, Vemulkonda Koneti Rao, Rob Robey, et al.
Archives of Dermatology|June 19, 2008
Sorafenib-induced eruptive melanocytic lesionsHeidi H Kong, Vincent Sibaud, Maria L Chanco Turner, et al.
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Role of radiotherapy in adrenocortical carcinomaJennifer Ho, Baris Turkbey, Maureen Edgerly, et al.
Cell Cycle (Georgetown, Tex.)|February 16, 2012
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatinRobert F Murphy, Edina Komlodi-Pasztor, Robert Robey, et al.
Journal of Medicinal Chemistry|September 2, 2005
Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profileErin S F Ma, W Douglas Bates, Armistead Edmunds, et al.
Chemotherapy Research and Practice|February 8, 2012
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 InhibitorXiaobing Liang, Yi Guo, William Douglas Figg, et al.
Pageof 24

Showing results (121-130 of 237) with videos related to

Sort By:
Pageof 24
Anti-Cancer Drugs|June 19, 2004
The clinical development of new mitotic inhibitors that stabilize the microtubuleSridhar Mani, Manuel Macapinlac, Sanjay Goel, et al.
Cell Cycle (Georgetown, Tex.)|April 17, 2008
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibitionMarianne S Poruchynsky, Dan L Sackett, Robert W Robey, et al.
Cancer Research|September 4, 2014
Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancersKrastan B Blagoev, Julia Wilkerson, Wilfred D Stein, et al.
The Journal of Clinical Endocrinology and Metabolism|November 21, 2014
Brain metastasis in patients with adrenocortical carcinoma: a clinical seriesMauricio Burotto, Nishant Tageja, Avi Rosenberg, et al.
Blood|March 6, 2002
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cellsMasaki Kitazono, Vemulkonda Koneti Rao, Rob Robey, et al.
Archives of Dermatology|June 19, 2008
Sorafenib-induced eruptive melanocytic lesionsHeidi H Kong, Vincent Sibaud, Maria L Chanco Turner, et al.
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Role of radiotherapy in adrenocortical carcinomaJennifer Ho, Baris Turkbey, Maureen Edgerly, et al.
Cell Cycle (Georgetown, Tex.)|February 16, 2012
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatinRobert F Murphy, Edina Komlodi-Pasztor, Robert Robey, et al.
Journal of Medicinal Chemistry|September 2, 2005
Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profileErin S F Ma, W Douglas Bates, Armistead Edmunds, et al.
Chemotherapy Research and Practice|February 8, 2012
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 InhibitorXiaobing Liang, Yi Guo, William Douglas Figg, et al.
Pageof 24